News

CPHI Awards Open for Entries in Multiple Categories

March 23, 2023

Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.

Invitae and Deerfield Management Team Up on Novel Therapeutics for Rare Diseases

March 22, 2023

Under a new partnership, Invitae and Deerfield Management will harness genetic and clinical testing data from patients to discover potential novel therapeutics for treating rare diseases.

Scorpius BioManufacturing Announces New Microbial Capacity and New Interim President

March 22, 2023

In addition to a new interim president, the company is opening new microbial capacity at its San Antonio facility and has plans to construct a commercial-scale facility in Manhattan, Kan.

TrakCel and Lonza Reach Integration Milestone to Combine Cell and Gene Therapy Manufacturing, Orchestration Solutions

March 22, 2023

The combined solutions are currently available on the market.

PurePep EasyClean Services Set to Accelerate Development and Manufacturing of Peptide-based Drugs

March 22, 2023

The services are based on the company’s PurePrep EasyClean (PEC) orthogonal peptide purification technology.

Lynparza Approved in UK as Combination Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer

March 22, 2023

The decision was based on results from the PROpel Phase III trial.

European Commission Approves Dupixent as First, Only Targeted Medicine for Children with Severe Atopic Dermatitis

March 22, 2023

This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.

Sanofi Drops Lantus US List Price by 78%, Capping Out-of-Pocket Costs at $35

March 21, 2023

Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance.

BioNTech and OncoC4 to Co-Develop mAb for Solid Tumor Indications

March 21, 2023

BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.

EMA Management Board Continues to Monitor Critical Shortages of Medicines

March 21, 2023

Additionally, the MSG discussed plans to mitigate shortages of antibiotics for the next autumn and winter season.